TIN 816
Alternative Names: TIN-816Latest Information Update: 05 Jun 2024
At a glance
- Originator Novartis Pharmaceuticals
- Class Anti-inflammatories; Enzymes; Hydrolases; Recombinant proteins
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute kidney injury
Most Recent Events
- 25 Apr 2024 Novartis completes a phase-II trial in Acute kidney injury in Belgium, France, Germany, Hungary and Spain (NCT05507437)
- 18 Jan 2024 Phase-II clinical trials in Acute kidney injury in Canada (IV) (NCT05996835)
- 18 Jan 2024 Phase-II clinical trials in Acute kidney injury in Turkey (IV) (NCT05996835)